Hedgehog pathway blockade inhibits melanoma cell growth in vitro and in vivo

Pharmaceuticals

Volumn 6, Issue 11, 2013, Pages 1429-1450

  O'Reilly, Kathryn E ^a   de Miera, Eleazar Vega Saenz ^a   Segura, Miguel F ^a,b   Friedman, Erica ^a   Poliseno, Laura ^c   Han, Sung Won ^a   Zhong, Judy ^a   Zavadil, Jiri ^a,d,e   Pavlick, Anna ^a   Hernando, Eva ^a   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c ISTITUTO TOSCANO TUMORI   (Italy)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

GLI2; Hedgehog; Melanoma; PTCH1; Smoothened

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOPAMINE; NOTCH RECEPTOR; PROTEIN PATCHED 1; SMALL INTERFERING RNA; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TRANSCRIPTION FACTOR GLI2; VEMURAFENIB; VISMODEGIB; WNT PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84887456935     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6111429     Document Type: Article

References (36)

1. National Cancer Institute. SEER Stat Fact Sheets: Melanoma of the Skin. Available online: http://seer.cancer.gov/statfacts/html/melan.html/ (accessed on 29 January 2013).
2. Garbe, C.; McLeod, G.R.; Buettner, P.G. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2000, 89, 1269-1278.
3. Howlader, N.; Noone, A.M.; Krapcho, M.; Garshell, J.; Neyman, N.; Altekruse, S.F.; Kosary, C.L.; Yu, M.; Ruhl, J.; Tatalovich, Z.; et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Available online: http://seer.cancer.gov/csr/1975_2009_pops09/ (accessed on 31 October 2003).
4. Bedikian, A.Y.; Millward, M.; Pehamberger, H.; Conry, R.; Gore, M.; Trefzer, U.; Pavlick, A.C.; de Conti, R.; Hersh, E.M.; Hersey, P.; et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J. Clin. Oncol. 2006, 24, 4738-4345.
5. Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507-2516.
6. Solit, D.; Sawyers, C.L. Drug discovery: How melanomas bypass new therapy. Nature 2010, 468, 902-903.
7. Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723.
8. Robert, C.; Thomas, L.; Bondarenko, I.; O'Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364, 2517-2526.
9. Zhang, K.; Wong, P.; Zhang, L.; Jacobs, B.; Borden, E.C.; Aster, J.C.; Bedogni, B. A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene 2012, 31, 4609-4618.
10. Huynh, C.; Poliseno, L.; Segura, M.F.; Medicherla, R.; Haimovic, A.; Menendez, S.; Shang, S.; Pavlick, A.; Shao, Y.; Darvishian, F.; et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One 2011, 6, e25264.
11. Tolcher, A.W.; Messersmith, W.A.; Mikulski, S.M.; Papadopoulos, K.P.; Kwak, E.L.; Gibbon, D.G.; Patnaik, A.; Falchook, G.S.; Dasari, A.; Shapiro, G.I.; et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 2012, 30, 2348-2353.
12. Imbimbo, B.P. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr. Top. Med. Chem. 2008, 8, 54-61.
13. Okamoto, R.; Tsuchiya, K.; Nemoto, Y.; Akiyama, J.; Nakamura, T.; Kanai, T.; Watanabe, M. Requirement of Notch activation during regeneration of the intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296, G23-G35.
14. Stecca, B.; Mas, C.; Clement, V.; Zbinden, M.; Correa, R.; Piguet, V.; Beermann, F.; Ruiz, I.; Altaba, A. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc. Natl. Acad. Sci. USA 2007, 104, 5895-900.
15. Alexaki, V.I.; Javelaud, D.; van Kempen, L.C.; Mohammad, K.S.; Dennler, S.; Luciani, F.; Hoek, K.S.; Juàrez, P.; Goydos, J.S.; Fournier, P.J.; et al. GLI2-mediated melanoma invasion and metastasis. J. Natl. Cancer Inst. 2010, 102, 1148-1159.
16. Das, S.; Harris, L.G.; Metge, B.J.; Liu, S.; Riker, A.I.; Samant, R.S.; Shevde, L.A. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J. Biol. Chem. 2009, 284, 22888-22897.
17. Rubin, L.L.; de Sauvage, F.J. Targeting the hedgehog pathway in cancer. Nat. Rev. Drug Discov. 2006, 5, 1026-1033.
18. Thayer, S.P.; di Magliano, M.P.; Heiser, P.W.; Nielsen, C.M.; Roberts, D.J.; Lauwers, G.Y.; Qi, Y.P.; Gysin, S.; Fernández-del Castillo, C.; Yajnik, V.; et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425, 851-856.
19. Kubo, M.; Nakamura, M.; Tasaki, A.; Yamanaka, N.; Nakashima, H.; Nomura, M.; Kuroki, S.; Katano, M. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res. 2004, 64, 6071-6074.
20. Berman, D.M.; Karhadkar, S.S.; Maitra, A.; Montes de Oca, R.; Gerstenblith, M.R.; Briggs, K.; Parker, A.R.; Shimada, Y.; Eshleman, J.R.; Watkins, D.N.; et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425, 846-851.
21. Watkins, D.N.; Berman, D.M.; Burkholder, S.G.; Wang, B.; Beachy, P.A.; Baylin, S.B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003, 422, 313-317.
22. Berman, D.M.; Karhadkar, S.S.; Hallahan, A.R.; Pritchard, J.I.; Eberhart, C.G.; Watkins, D.N.; Chen, J.K.; Cooper, M.K.; Taipale, J.; Olson, J.M.; et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002, 297, 1559-1561.
23. Merchant, A.A.; Matsui, W. Targeting hedgehog-A cancer stem cell pathway. Clin. Cancer Res. 2010, 16, 3130-3140.
24. Takebe, N.; Warren, R.Q.; Ivy, S.P. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res. 2011, 13, 211.
25. Santini, R.; Vinci, M.C.; Pandolfi, S.; Penachioni, J.Y.; Montagnani, V.; Olivito, B.; Gattai, R.; Pimpinelli, N.; Gerlini, G.; Borgognoni, L.; et al. Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells 2012, 30, 1808-1818.
26. Jalili, A.; Mertz, K.D.; Romanov, J.; Wagner, C.; Kalthoff, F.; Stuetz, A.; Pathria, G.; Gschaider, M.; Stingl, G.; Wagner, S.N. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo. PLoS One 2013, 8, e69064.
27. Fang, D.; Nguyen, T.K.; Leishear, K.; Finko, R.; Kulp, A.N.; Hotz, S.; Van Belle, P.A.; Xu, X.; Elder, D.E.; Herlyn, M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 65, 9328-9337.
28. Rose, A.E.; Poliseno, L.; Wang, J.; Clark, M.; Pearlman, A.; Wang, G.; de Miera, E.C.; Medicherla, R.; Christos, P.J.; Shapiro, R.; et al. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res. 2011, 71, 2561-2571.
29. Bogunovic, D.; O'Neill, D.W.; Belitskaya-Levy, I.; Vacic, V.; Yu, Y.L.; Adams, S.; Darvishian, F.; Berman, R.; Shapiro, R.; Pavlick, A.C.; et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. USA 2009, 106, 20429-20434.
30. Schreck, K.C.; Taylor, P.; Marchionni, L.; Gopalakrishnan, V.; Bar, E.E.; Gaiano, N.; Eberhart, C.G. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin. Cancer Res. 2010, 16, 6060-6670.
31. Dijkgraaf, G.J.; Alicke, B.; Weinmann, L.; Januario, T.; West, K.; Modrusan, Z.; Burdick, D.; Goldsmith, R.; Robarge, K.; Sutherlin, D.; et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011, 71, 435-444.
32. Buonamici, S.; Williams, J.; Morrissey, M.; Wang, A.; Guo, R.; Vattay, A.; Hsiao, K.; Yuan, J.; Green, J.; Ospina, B.; et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2010, 2, 51-70.
33. Metcalfe, C.; de Sauvage, F.J. Hedgehog fights back: Mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 2011, 71, 5057-5061.
34. Li, C.; Chi, S.; Xie, J. Hedgehog signaling in skin cancers. Cell. Signal. 2011, 23, 1235-1243.
35. Mas, C.; Ruiz, I.; Altaba, A. Small molecule modulation of HH-GLI signaling: current leads, trials and tribulations. Biochem. Pharmacol. 2010, 80, 712-723.
36. Takebe, N.; Harris, P.J.; Warren, R.Q.; Ivy, S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8, 97-106.